17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
about
Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).Comparative genomic hybridization analysis of invasive ductal breast carcinomas in the Chinese population.
P2860
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@ast
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@en
type
label
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@ast
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@en
prefLabel
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@ast
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@en
P2093
P2860
P356
P1476
17p12 deletion in breast cancer predicts resistance to neoadjuvant chemotherapy.
@en
P2093
DO-Youn Oh
Eunyoung Ko
Hyeong-Gon Moon
In-Ae Park
Jihyoung Cho
Jung Hoon Woo
Kap-Seok Yang
Ki-Tae Hwang
Seock-Ah Im
Song-Ju Yang
P2860
P304
P356
10.3892/ETM.2011.299
P577
2011-06-29T00:00:00Z